Skip to main content

Top navigation

  • Fight Like Cal Ripken, Jr.
  • GSA Award
  • For Veterans
  • Provider Resources
  • Contact Us
  • +1 844 396 7663
Bio-Techne Exosome logo

Main navigation

  • Physicians
    • ExoDx™ Prostate Test: At-Home Collection Kit
    • ExoDx™ Prostate Test
    • Challenge of Prostate Cancer
    • Physician FAQs
    • What are Exosomes
    • Publications and Abstracts
    • Investigator Initiated Research (IIR) Program
  • Patients
    • The ExoDx Prostate Test
    • Physician Locator
    • Understanding PSA Levels
    • About Prostate Cancer
    • ZERO - The End of Prostate Cancer
    • Patient FAQs
    • Patient Assistance Program
    • Billing Information
  • Pharma Services
    • Working with Us
    • Biomarker Discovery
    • Assay Development
    • Exosome Enrichment Capabilities
    • Companion Diagnostics (CDx) and Clinical Trial Support
  • Our Technology
    • Our Technology
    • Sensitivity to RNA/DNA
    • Extraction Procedures
    • Superiority to cfDNA and CTCs
  • News & Resources
    • Press
    • Webinars
    • Events

Top navigation

  • Fight Like Cal Ripken, Jr.
  • GSA Award
  • For Veterans
  • Provider Resources
  • Contact Us
  • +1 844 396 7663

Press

  • Exosome Diagnostics Achieves ISO 13485:2016 Certification

    Press Jun 13, 2018

  • Exosome Diagnostics Announces Bladder Cancer Surveillance Panel

    Press May 22, 2018

  • Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA

    Press May 17, 2018

  • Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain

    Press May 15, 2018

  • Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test

    Press May 09, 2018

  • Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test

    Press May 08, 2018

  • Exosome Diagnostics Obviates Tissue Biopsies

    Press Apr 17, 2018

  • Exosome Diagnostics Announces Publication of a Highly Sensitive Exosome Based Liquid Biopsy Test for EGFR T790M Mutations in Plasma from Non-Small Cell Lung Cancer Patients

    Press Mar 20, 2018

  • Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor

    Press Mar 14, 2018

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Next page Next ›
  • Last page Last »

(844) 396-7663
exosomedx.info@bio-techne.com
266 Second Ave, Suite 200
Waltham, MA 02451

Footer menu

  • About Bio-Techne
  • Management Team
  • Careers
  • Investors
  • Corporate Responsibility
  • Accreditation and Licensure

Social navigation

  • Facebook
  • Twitter
  • LinkedIn

Iso LogoThis test was evaluated and its performance characteristics determined by Exosome Diagnostics, Inc. Exosome Diagnostics is certified under the Clinical Laboratory Improvement Amendments (CLIA) Act of 1988 as qualified to perform high complexity clinical testing. CLIA number: 22D2093470.  Exosome Diagnostics and ExoDx are registered trademarks of Exosome Diagnostics, Inc.

© 2022 ExoDx

Bottom footer navigation

  • Privacy Policy